Uniqure NV (QURE)

Name: Uniqure NV (QURE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Uniqure NV (QURE)

Stock Card

$44.86

$-1.37 (-2.96%)

As on 03-Sep-2026 16:00EDT

Market cap

$3,380 Mln

Revenue (TTM)

$19 Mln

P/E Ratio

P/B Ratio

10.6

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Uniqure NV (QURE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 44.03 High: 46.03

52 Week Range

Low: 8.73 High: 71.50

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.4
Debt to Equity

0.2
Book Value

$--
EPS

$-4.1
Face value

--
Shares outstanding

69,366,412

10 Years Aggregate

CFO

$-461.18 Mln

EBITDA

$-590.69 Mln

Net Profit

$-718.97 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Uniqure NV (QURE)	87.5	2.8	67.6	163.7	72.6	7.5	19.3
BSE Sensex	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Uniqure NV (QURE)	35.5	-70.1	9.3	-42.6	-49.6	148.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Uniqure NV (QURE)	44.9	3,379.5	18.7	-252.2	-1,047.2	-96.5	--	10.6
ATAI Life Sciences BV (ATAI)	7.3	2,703.6	4.5	-668.2	-15,198.8	-335.5	--	15.5
InflaRx N.V. - ADR	2.2	328.6	0.0	-39.1	281,529.0	-41.7	--	2.0
Pharvaris BV (PHVS)	35.7	2,479.6	0.0	-171.6	--	-60	--	7.4
ProQR Therapeutics N.V. - ADR	2.1	323.2	18.5	-42.3	-230.0	-65.7	--	3.5
Qiagen N.V. - ADR	43.9	9,271.6	2,100.4	409.3	23.8	11.5	22.7	2.7

Shareholding Pattern

View Details

About Uniqure NV (QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.... Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Read more

CEO & Executive Director

Mr. Matthew Craig Kapusta
CEO & Executive Director

Mr. Matthew Craig Kapusta CPA
Headquarters

Amsterdam
Website

https://www.uniqure.com

FAQs for Uniqure NV (QURE)

What is the current share price of Uniqure NV (QURE) Today?

The share price of Uniqure NV (QURE) is $44.86 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Uniqure NV (QURE) has given a return of 72.63% in the last 3 years.

What is the current PB & PE ratio of Uniqure NV (QURE)?

Since, TTM earnings of Uniqure NV (QURE) is negative, P/E ratio is not available.
The P/B ratio of Uniqure NV (QURE) is 10.60 times as on 28-Aug-2026, a 43 premium to its peers’ median range of 7.40 times.

PE & PB ratio at the end of financial year.